ENXTPA:DBVBiotechs
Will Positive Phase 3 VITESSE Peanut Patch Data Change DBV Technologies' (ENXTPA:DBV) Narrative?
DBV Technologies recently presented additional positive data from its successful Phase 3 VITESSE trial of the VIASKIN Peanut Patch for peanut-allergic children aged 4 to 7 at the 2026 AAAAI Annual Meeting in Philadelphia.
The data showed clinically meaningful increases in the eliciting dose for treated children versus placebo, highlighting both potential protection against reactions and the risks of remaining untreated.
Next, we will examine how these Phase 3 VITESSE results, particularly...